Thirteen point two months. That is how long patients with previously treated metastatic pancreatic cancer lived on a once-daily pill in the RASolute 302 trial, against 6.7 months on chemotherapy. On 26 August the FDA approved that pill as RASONQUE (daraxonrasib), the first medicine to directly inhibit RAS, the gene family that drives more than 90% of pancreatic tumours. Then came the list price: $39,800 for a 30-day supply.
The launch math is aggressive: a $39,800 monthly list price, RBC Capital Markets projecting $1.1 billion in US sales for 2027 and roughly $11.5 billion at peak, Evercore putting 2034 pancreatic sales at $15.1 billion.
Two risks decide whether the story holds: payer behaviour, because insurance was not ready when the drug was approved, and the next readouts in earlier treatment lines and other tumours, where the real RAS market sits.
Some context before the paywall. Pancreatic cancer kills about 55,000 Americans a year and has a five-year survival rate near 13%. Its main driver, KRAS, was discovered more than four decades ago and spent most of that time labelled undruggable: a smooth protein with no obvious pocket for a small molecule. This approval is the first crack in that wall.
RASolute 302, second-line metastatic PDAC
Median overall survival (OS) in the full trial population, 248 patients on daraxonrasib against 252 on chemotherapy. · New England Journal of Medicine, 2026
Forty years of calling RAS undruggable
RAS is not one gene. It is a family of three, KRAS, NRAS and HRAS, that switch growth signals on and off inside cells. Mutations park the switch in the on position. KRAS is mutated in about a quarter of all human tumours, and in pancreatic cancer the rate is over 90%.
The industry tried for decades. Covalent KRAS G12C inhibitors finally reached patients, but only for one mutation in one disease: sotorasib (Amgen's Lumakras) and adagrasib (now Bristol Myers Squibb's Krazati) treat G12C-mutant lung cancer. Neither became the seller its launch price implied, and G12C is a small slice of the RAS universe. Pancreatic cancer is dominated by G12D, G12V and G12R, plus patients with no detected RAS mutation at all.
Revolution Medicines built RASONQUE on a different idea.
The drug is a so-called RAS(ON) tri-complex inhibitor. Rather than competing with the protein's normal fuel, it locks RAS in its active state with a second protein, then blocks the signalling surface. It is multi-selective, which is a careful way of saying it covers several RAS variants at once. That breadth, not potency against a single mutation, is what let the FDA approve it without requiring a companion diagnostic test.
The trial that moved the median
RASolute 302 enrolled 500 patients whose metastatic pancreatic cancer had already progressed past one line of chemotherapy. Patients drew RASONQUE at 300 mg once a day or an investigator-chosen chemo regimen. The primary endpoints were progression-free survival (PFS) and overall survival (OS) in the RAS G12 population; the company also measured everyone else.
The results, published in the New England Journal of Medicine and presented at ASCO in May, were large enough that oncologists gave them a standing ovation.
| Measure (RASolute 302) | RASONQUE | Chemotherapy |
|---|---|---|
| Median overall survival, full population | 13.2 months | 6.7 months |
| Hazard ratio for death | 0.40 (P<0.001) | |
| Median PFS, full population | 7.2 months | 3.6 months |
| Objective response rate | 31.6% | 11.2% |
| Dropout for treatment-related side effects | 1.2% | 11.2% |
Source: RASolute 302, New England Journal of Medicine, 2026
The hazard ratio of 0.40 held in both the RAS G12 group and the broader population, meaning patients without a detectable RAS mutation still benefited. Fewer patients on the pill stopped treatment for side effects than on chemo, 1.2% against 11.2%. That profile is why Dana-Farber's Brian Wolpin, the trial's principal investigator, called the data a signal that directly inhibiting RAS can make a real difference in this disease.
Read that framing twice. In a cancer where the median second-line patient died within seven months, a pill that roughly doubles survival is a clinical event that changes practice, not marketing.
These results suggest that the science has guided us in a productive direction, and that this first medicine that broadly targets RAS is indeed an effective therapy that has the potential to benefit many patients with pancreatic cancer.— Brian Wolpin, Dana-Farber Cancer Institute, principal investigator, RASolute 302
Priced like a franchise, not a second-line drug
Revolution set a wholesale acquisition cost of $39,800 for a 30-day supply. That is about $477,000 a year, more than double the list price of Keytruda, the best-selling cancer medicine in the world. The company's own analysts had expected $25,000 to $30,000.
The price says the company is pricing for the label it wants, not the label it has.
RASONQUE pricing, US launch
Wholesale acquisition cost disclosed by Revolution Medicines on its launch call, 26 August 2026. · BioPharma Dive, 2026
Sell-side models are correspondingly large. RBC Capital Markets' Leonid Timashev sees $28 million in the third quarter of 2026, $148 million in the fourth, and $1.1 billion for 2027, with about $11.5 billion at peak. Evercore ISI's Cory Kasimov raised his estimate to $2.4 billion for next year and $15.1 billion by 2034 for pancreatic cancer alone, and up to $20.8 billion at peak if the drug reaches other RAS-driven tumours.
Those numbers rest on the label's flexibility. RASONQUE is approved for patients who had at least one prior therapy "or who are not candidates for multiagent systemic therapy". That second clause lets a physician prescribe it earlier, and analysts read it as an opening toward first-line use. Kasimov wrote that Rasonque "has the ingredients to be one of the fastest oncology launches in history, if not the fastest".
More than 2,000 patients had already received the drug through compassionate use before approval, which shortens the launch curve.
The lag between the FDA and the insurer
Here is the friction the sell-side models do not price. STAT reported on 8 September that patients were caught between approval and coverage: insurers were not ready, and weeks can pass before a plan covers a $39,800 monthly prescription. For a drug with no second-line alternative, most payers will eventually cover it. The open question is how many patients lose weeks they do not have in the interim, and whether that gap feeds the company's own patient-support program, (ON)Path, which absorbs some of the cost.
FDA's own language was unusually strong. Angelo de Claro, director of the agency's Oncology Center of Excellence, said the drug "showed unprecedented results in an area of high unmet need". The FDA has been burned before by first-in-class enthusiasm. It approves on the data in front of it.
Tolerability. The label carries warnings for skin toxicity, diarrhoea, gastrointestinal perforation and lung inflammation. Rash and mouth sores are common.
Payer step therapy. A plan can route patients through cheaper chemo first, which the label does not forbid.
Commercial precedent. The two earlier KRAS drugs reached the market and still did not become blockbusters.
European regulators are reviewing the drug under a phased process that could produce a faster decision, and daraxonrasib holds orphan designation in the EU. The company is running a first-line Phase 3 trial, testing the drug in the adjuvant setting, and running a Phase 3 in non-small cell lung cancer.
That pipeline is why the market caps Revolution at more than $45 billion, above Biogen and Alnylam, after a five-fold share rise in a year. Strip out the future indications and the current label supports a fraction of that valuation. Every forward-looking dollar depends on readouts that have not happened.
What happens to the RAS market a year from now?
Probability: 65% — the label already allows earlier use, the safety profile supports it, and no competitor is close in this indication.
✅ Arguments for
Dropout for side effects was 10 percentage points lower than chemo, which matters for a drug given to people already weakened by the disease.
No rival is in late-stage development for this exact second-line population.
Confirmation criteria: the first-line Phase 3 trial stays on schedule and shows an OS signal; EMA approval lands within 12 months.
❌ Arguments against
Skin and gastrointestinal toxicity will exclude a meaningful minority of patients, especially in the sicker second-line group.
The commercial record of first-generation RAS drugs is a warning about how slowly new mechanisms convert into revenue.
Disconfirmation criteria: the first-line trial misses; insurers restrict use for a full quarter; EMA demands extra data.
What the approval says about the wider field
RASONQUE matters beyond one company because it reopens a whole drugging hypothesis. A generation of RAS programmes stalled after G12C disappointed. The multi-selective approach now has a regulatory seal, which changes how venture money will treat RAS-adjacent platforms, degraders and combination trials. Expect deal activity around RAS(ON) and mutant-selective assets to pick up, and expect the smart buyers to wait for the first-line data before paying franchise prices.
Timing and outcome of the first-line Phase 3 trial in metastatic pancreatic cancer.
First full quarter of prescriptions and net price, once discounts and patient assistance are stripped out.
The EMA phased review decision for Europe.
Whether insurers allow earlier-line use or force step therapy through chemotherapy.
Development scenarios
🟢 Optimistic scenario (25%)
Implications: the current market cap starts to look cheap against $11.5 billion of peak sales, and buyout interest returns at a premium.
🟡 Base-case scenario (55%)
Implications: sales reach the low billions by 2027, the stock consolidates, and value creation shifts to the next data readout rather than the launch itself.
🔴 Pessimistic scenario (20%)
Implications: a $45 billion valuation built on future indications deflates toward the current-label multiple, and RAS enthusiasm cools across the sector.
Forty years of failure give the approval its weight. What matters for anyone allocating capital is the gap between the clinical event and the commercial outcome. The pill works. Whether it is worth $477,000 a year, and whether the first-line data justify a $45 billion company, are separate questions, and the next twelve months answer both.